When it comes to treating chronic inflammatory demyelinating polyneuropathy (CIDP) with subcutaneous immunoglobulin (SCIG), the patient can be trained by a professional to administer the treatment themselves. So what counseling strategies can we use to help patients successfully transition from intravenous to SCIG therapy? Join Dr. Jennifer Caudle as she gains insights from Dr. David Saperstein, Director of the Center for Complex Neurology, EDS, and POTS in Phoenix, Arizona, and Associate Professor of Clinical Neurology at the University of Arizona College of Medicine.